WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 314222
CAS#: 150812-12-7 (free base)
Description: Ezogabine, also known as Retigabine, is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. Ezogabine works primarily as a potassium channel opener—that is, by activating a certain family of voltage-gated potassium channels in the brain. This mechanism of action is unique among antiepileptic drugs, and may hold promise for the treatment of other neurologic conditions, including migraine, tinnitus and neuropathic pain. (Source: http://en.wikipedia.org/wiki/Retigabine). Ezogabine is discontinued (DEA controlled substance).
MedKoo Cat#: 314222
CAS#: 150812-12-7 (free base)
Chemical Formula: C16H18FN3O2
Exact Mass: 303.13831
Molecular Weight: 303.33
Elemental Analysis: C, 63.35; H, 5.98; F, 6.26; N, 13.85; O, 10.55
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 150812-12-7 (free base) 150812-13-8 (2HCl)
Synonym: D23129; D-23129; D 23129; GKE 841; GKE-841; GKE841; GW 582892X; WAY 143841; WAY-143841; WAY143841; Ezogabine; Retigabine; Trobalt; Potiga.
IUPAC/Chemical Name: ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate
InChi Key: QUAXPMCGRPZNEG-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H18FN3O2/c1-3-22-16(21)19-15-9-8-13(10-14(15)18)20(2)12-6-4-11(17)5-7-12/h4-10H,3,18H2,1-2H3,(H,19,21)
SMILES Code: O=C(OCC)NC1=CC=C(N(C2=CC=C(F)C=C2)C)C=C1N
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 303.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Faulkner MA, Burke RA. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel. Expert Opin Drug Saf. 2013 Nov;12(6):847-55. doi: 10.1517/14740338.2013.823399. Epub 2013 Jul 25. Review. PubMed PMID: 23883095.
2: Amabile CM, Vasudevan A. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures. Pharmacotherapy. 2013 Feb;33(2):187-94. doi: 10.1002/phar.1185. Review. PubMed PMID: 23386597.
3: Yamada M, Welty TE. Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults. Ann Pharmacother. 2012 Oct;46(10):1358-67. doi: 10.1345/aph.1R153. Epub 2012 Sep 18. Review. PubMed PMID: 22991134.
4: Verma A, Kumar R, Kumar M. Ezogabine: development and role in the management of epileptic seizures. Mini Rev Med Chem. 2013 Apr 1;13(5):697-705. Review. PubMed PMID: 22931529.
5: Splinter MY. Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review. Clin Ther. 2012 Sep;34(9):1845-56.e1. doi: 10.1016/j.clinthera.2012.07.009. Epub 2012 Aug 21. Review. PubMed PMID: 22917854.
6: Hopkins CR. ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine). ACS Chem Neurosci. 2012 Aug 15;3(8):632. doi: 10.1021/cn3000789. Review. PubMed PMID: 22896808; PubMed Central PMCID: PMC3419453.
7: Orhan G, Wuttke TV, Nies AT, Schwab M, Lerche H. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. Expert Opin Pharmacother. 2012 Aug;13(12):1807-16. doi: 10.1517/14656566.2012.706278. Epub 2012 Jul 12. Review. PubMed PMID: 22783830.
8: Brickel N, Gandhi P, VanLandingham K, Hammond J, DeRossett S. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12. doi: 10.1111/j.1528-1167.2012.03441.x. Epub 2012 Mar 16. Review. PubMed PMID: 22428574.
9: Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012 Mar;53(3):412-24. doi: 10.1111/j.1528-1167.2011.03365.x. Epub 2012 Jan 5. Review. PubMed PMID: 22220513.
10: Chung SS, Kelly K, Schusse C. New and Emerging Treatments for Epilepsy: Review of Clinical Studies of Lacosamide, Eslicarbazepine Acetate, Ezogabine, Rufinamide, Perampanel, and Electrical Stimulation Therapy. J Epilepsy Res. 2011 Dec 30;1(2):35-46. eCollection 2011 Dec. Review. PubMed PMID: 24649444; PubMed Central PMCID: PMC3952328.
CAS#150812-12-7 (free base);